We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Watson R&D Spending Rises for Generic Pharmaceuticals
Watson R&D Spending Rises for Generic Pharmaceuticals
November 10, 2009
Watson Pharmaceuticals has increased its generic R&D spending by 17 percent to $37 million during the third quarter as it awaits FDA action on about 60 ANDAs under review.